Incyte Corp. (INCY)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Apr 22, 2025

$57.38

P/E Ratio

370.43

Market Cap

$11.1B

Loading...
Description
Add to research
View more

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Metrics
Add to research
View more

Overview

  • HQWilmington, DE
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerINCY
  • Price$57.38+1.02%

Trading Information

  • Market cap$11.10B
  • Float98.44%
  • Average Daily Volume (1m)2,162,017
  • Average Daily Volume (3m)1,988,688
  • EPS$0.16

Company

  • Revenue$4.24B
  • Rev growth (1yr)14.76%
  • Net income$32.62M
  • Gross margin91.09%
  • EBITDA margin3.99%
  • EBITDA$169.39M
  • EV$12.44B
  • EV/Revenue2.93
  • P/E370.43
  • P/S2.85
  • P/B3.22
  • Debt/Equity1.75
Documents
Add to research
View more